Abstract 882P
Background
While strong evidence indicates quitting smoking reduces the risk of developing head and neck cancer (HNC), it remains unclear whether patients who smoke could still benefit from quitting after HNC diagnosis. We investigated the impact of postdiagnosis smoking cessation on the survival of patients with HNC who smoked at diagnosis.
Methods
This prospective study included 1,298 participants who were diagnosed with HNC in the United Kingdom (Head and Neck 5000 study, recruitment: 2011-2014), and 4 countries in Latin America (Brazil, Argentina, Uruguay, and Colombia - INTERCHANGE study, recruitment: 2011-2017) who actively smoked at diagnosis. Participants have been actively followed since their diagnosis to collect regular information on their smoking behavior and disease status. Overall survival was evaluated using extended Kaplan-Meier curves and time-dependent Cox proportional hazards regression models.
Results
During the follow-up, 442 participants (34%) reported quitting smoking, and 571 deaths were recorded. Median survival time was 17 months higher when patients quit vs. continued smoking (median survival time = 6.6 vs. 5.2 years, p<0.001). At 5-years, the survival rate was significantly higher when patients quit vs. continued smoking (61.0% vs. 50.6%, p<0.001). After accounting for the quitting time and adjusting for potential confounders, quitting smoking was associated with 33% lower risk of death compared to continued smoking (HR=0.67, 95%CI=0.56-0.81). Stratified analyses revealed consistent survival benefits associated with quitting smoking among all patient subgroups, including those who reported mild-moderate vs. heavy smoking, and patients who were diagnosed with earlier vs. later-stage tumors. The benefits of quitting smoking were also evident across various HNC subtypes.
Conclusions
Quitting smoking after HNC diagnosis may significantly reduce the risk of death and improve survival among patients who smoke. These findings underscore the importance of post-diagnosis smoking cessation interventions as part of comprehensive cancer care for HNC patients.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
772P - Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (C-PATROL): Analysis by BRCA mutation status from a real-world study
Presenter: Jalid Sehouli
Session: Poster session 02
773P - Role of tumor primary chemosensitivity assessed by modeled CA-125 KELIM to predict complete interval debulking surgery (IDS) in ovarian carcinoma patients treated with neo-adjuvant chemotherapy and immunotherapy: A GINEGEPS/GINECO study of the NeoPembrOv and INeOV trials
Presenter: Pauline Corbaux
Session: Poster session 02
774P - Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database
Presenter: Morgan Zenatri
Session: Poster session 02
775P - Association between chemotherapy response score (CRS) and tumour homologous recombination deficiency (tHRD) in women with newly diagnosed FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Fiona Britton
Session: Poster session 02
776P - Liquid biopsy for the determination of homologous recombination deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study
Presenter: Alexandre Harlé
Session: Poster session 02
777P - A phase II study of the efficacy of olaparib maintenance monotherapy for patients with HRD-positive, newly diagnosed, advanced, high-grade ovarian cancer, evaluated by whole-exome sequencing (MSBM-OL)
Presenter: Katsutoshi Oda
Session: Poster session 02
778P - Efficacy and safety of pamiparib monotherapy in recurrent ovarian cancer (rOC) after prior PARPi exposure: A prospective, open label, single-arm, phase II study
Presenter: Jianqing Zhu
Session: Poster session 02
779P - Testing unselected women with newly diagnosed high-grade serous ovarian cancer (HGSOC) for germline pathogenic variants (PVs) in mismatch repair (MMR) genes is unnecessary
Presenter: Laura Spurgeon
Session: Poster session 02
780P - Propensity-score matching analysis for efficacy of platinum-based versus non-platinum chemotherapy in patients with “platinum-resistant” ovarian cancer (PROC): Real-world recent cohort study
Presenter: Alexey Rumyantsev
Session: Poster session 02
781P - Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation (C-PATROL): Overall survival (OS) in predefined subgroups
Presenter: Frederik Marmé
Session: Poster session 02